Dimerix strikes $120m licensing deal for kidney drug in Middle East
Dimerix strikes $120m licensing deal for kidney drug in Middle East
Source: stockhead.com.au
Stay updated with breaking news from Advanz Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dimerix strikes $120m licensing deal for kidney drug in Middle East
Taiba will oversee the complete sales and expenditures linked to the marketing of the product.
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and
Dr. Reddy's gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development